Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2023
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2023
OSAKA, Japan, June 26, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2024 (the "Annual Report") with the U.S. Securities and Exchange Commission (the "SEC") on June 26, 2024. The Annual Report can be accessed on Takeda's website at: https://www.takeda.com/investors/sec-filings-and-security-reports/.
2024年6月26日，日本大阪——武田製藥（SKYLINE（TAK-935-3001）是一項多中心、隨機、雙盲的3期研究，評估了Soticlestat（TAK-935）與標準板的聯合用藥與安慰劑和標準板的聯合用藥在難治性德拉維特綜合徵（DS）患者中的療效。）宣佈已向美國證券交易所（"SEC"）提交了截至2024年3月31日的財政年度的20-F表格的年度報告（"年度報告"），日期爲2024年6月26日。年度報告可以在武田公司的網站上訪問：https://www.takeda.com/investors/sec-filings-and-security-reports/.
In addition, Takeda will also provide a hard copy of the Annual Report, which includes its most recent complete audited financial statements free of charge to any shareholder upon request. Please contact Takeda Investor Relations by e-mail at takeda.ir.contact@takeda.com.
此外，武田公司將免費提供最新完整審計財務報表的硬拷貝年度報告給任何股東。請通過電子郵件聯繫武田投資者關係：takeda.ir.contact@takeda.com.
About Takeda
關於武田公司 武田公司致力於爲人們創造更健康的未來，爲世界帶來更光明的前景。我們的核心治療和業務領域包括消化道和炎症、罕見病、血漿衍生治療、腫瘤、神經科學和疫苗，旨在發現和推出改變生命的治療方案。與我們的合作伙伴一道，通過我們具有活力和多樣化的管道，我們的目標是改善患者的體驗，推進新的治療選擇。作爲總部位於日本的基於價值觀和以研發爲驅動的生物醫藥公司的領導者，我們的指導方針是致力於患者、我們的員工和地球的保護。我們在大約80個國家和地區的員工是由我們的使命和超過兩個世紀以來定義我們的價值觀所驅動的。有關更多信息，請訪問www.takeda.com。
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Takeda專注於爲人們創造更好的健康和更美好的未來。我們的目標是在我們的核心治療和業務領域，包括腸胃炎症、罕見疾病、血漿衍生療法、腫瘤學、神經科學和疫苗學中發現和提供變革人生的治療方案。與我們的夥伴一起，我們的目標是通過我們充滿活力和多樣化的流水線，改善患者的體驗並推動新的治療選擇的先鋒。作爲日本總部設在日本的一家領先的以價值爲導向的研發型生物製藥公司，我們是由我們對患者、人民和地球的承諾所引導的。我們在大約80個國家和地區的員工以我們的宗旨爲主導，並以已經定義我們兩個多世紀的價值爲根基。有關更多信息，請訪問www.takeda.com.
譯文內容由第三人軟體翻譯。